Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $58.28 in the prior trading day, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $59.72, up 2.48%. In other words, the price has increased by $2.48 from its previous closing price. On the day, 1.14 million shares were traded. CRSP stock price reached its highest trading level at $60.0 during the session, while it also had its lowest trading level at $56.6.
Ratios:
Our goal is to gain a better understanding of CRSP by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.81 and its Current Ratio is at 17.81. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
On December 11, 2023, TD Cowen Downgraded its rating to Underperform which previously was Market Perform but kept the price unchanged to $30.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 15 ’24 when Kulkarni Samarth sold 19,582 shares for $59.91 per share. The transaction valued at 1,173,232 led to the insider holds 208,122 shares of the business.
Kulkarni Samarth sold 20,000 shares of CRSP for $1,449,628 on Mar 15 ’24. The Chief Executive Officer now owns 208,122 shares after completing the transaction at $72.48 per share. On Mar 15 ’24, another insider, Prasad Raju, who serves as the Chief Financial Officer of the company, sold 3,524 shares for $72.69 each. As a result, the insider received 256,160 and left with 6,476 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 5071308800 and an Enterprise Value of 3198110464. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.66 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 11.77 whereas that against EBITDA is -11.462.
Stock Price History:
Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $37.55. The 50-Day Moving Average of the stock is 2.51%, while the 200-Day Moving Average is calculated to be 0.06%.
Shares Statistics:
The stock has traded on average 1.31M shares per day over the past 3-months and 1097490 shares per day over the last 10 days, according to various share statistics. A total of 84.92M shares are outstanding, with a floating share count of 81.12M. Insiders hold about 4.47% of the company’s shares, while institutions hold 66.74% stake in the company. Shares short for CRSP as of 1715731200 were 15334922 with a Short Ratio of 11.70, compared to 1713139200 on 14744982. Therefore, it implies a Short% of Shares Outstanding of 15334922 and a Short% of Float of 20.48.
Earnings Estimates
The dynamic stock of CRISPR Therapeutics AG (CRSP) is currently attracting attention from 22.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$1.51 for the current quarter, with a high estimate of -$1.08 and a low estimate of -$1.91, while EPS last year was -$0.98. The consensus estimate for the next quarter is -$1.39, with high estimates of -$0.43 and low estimates of -$1.97.
Analysts are recommending an EPS of between -$3.56 and -$7.24 for the fiscal current year, implying an average EPS of -$5.62. EPS for the following year is -$4.55, with 22.0 analysts recommending between $5.04 and -$8.71.
Revenue Estimates
A total of 22 analysts have provided revenue estimates for CRSP’s current fiscal year. The highest revenue estimate was $458.4M, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $63.18M. In the same quarter a year ago, actual revenue was $371.21M
